BioCentury
ARTICLE | Targets & Mechanisms

New route for old cancer agents

July 17, 2014 7:00 AM UTC

Researchers at the University of Wisconsin-Madison and Cellectar Biosciences Inc. have exploited differences in lipid architecture between cancer and normal cells to create compounds that deliver radiolabels selectively to different types of malignant cells while sparing healthy ones.1

The group has started multiple clinical trials of its agents for imaging, radiotherapy and intraoperative tumor margin detection...